Novartis AG’s radioligand therapy, Pluvicto, a bestseller for the company that has been restructuring itself, continues to show strong growth in the third quarter of 2023, according to its most recent financial results. Sales were up 217% from the same quarter in 2022 at $256 million. Analysts are predicting blockbuster sales. Adding to the momentum were new data from the phase III PSMAfore study of Pluvicto (lutetium [177Lu] vipivotide tetraxetan), in second-line cancer, hitting its primary endpoint of radiographic progression-free survival in treating prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer after treatment with androgen receptor pathway inhibitor therapy.
Immutep Ltd.’s lead candidate, eftilagimod (IMP-321, efti), a lymphocyte activation gene-3 (LAG-3) fusion protein and major histocompatibility complex class II agonist, delivered an overall survival benefit of 35.5 months in the TACTI-002 trial that combined efti with Merck & Co. Inc.’s Keytruda (pembrolizumab) as first-line treatment of non-small-cell lung cancer (NSCLC) at two years follow-up.
No matter how you look at it, guiding percutaneous coronary interventions to treat complex lesions with optical coherence tomography (OCT) or intravascular ultrasound (IVUS) produces similar results in patients with complex lesions, a study presented Oct. 23 at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco indicated.
Some cancers with a poor prognosis have had no new treatments in decades. Advances in the genetic characterization of these tumors now offer a range of possibilities for the development of new therapies that could completely change the quality of life and survival of these patients.
Researchers from Loxo Oncology at Eli Lilly and Co. recently reported the discovery and preclinical evaluation of a new highly potent and selective pan-KRAS inhibitor, LY-4066434, being developed for the treatment of cancer.
Epithelial cell adhesion molecule (EpCAM) is involved in cancer cell invasion while it acts as a negative regulator of adhesion. EpCAM is overexpressed in several cancer types, such as colorectal, ovarian or gastric cancer, and its expression is associated with a worse prognosis.
Artificial intelligence (AI) is in full development, and advances are already used in many fields, including medicine. In oncology, these tools can identify a tumor in an image with 99% accuracy. But they can also miss it if the algorithm was not developed with the right data or the correct decisions. The 2023 European Society for Medical Oncology (ESMO) Congress brought together in Madrid doctors and deep learning experts to discuss the challenges and advances of AI in this area. And what’s better than asking an AI what its trainer has told it about AI?
Harpoon Therapeutics Inc. provided updated interim monotherapy data from 71 patients in its phase I/II trial testing HPN-328 in small-cell lung cancer (SCLC) and other neuroendocrine tumor types in a poster at the European Society of Medical Oncology Congress (ESMO). Wall Street immediately began comparing the compound, which takes aim at delta-like ligand 3 (DLL3) with a similar prospect from Amgen Inc. that recently yielded promising results.
Medtronic plc got a jump on its cardiology competitors with big news ahead of the Transcatheter Cardiovascular Therapeutics (TCT) conference that starts on Oct 24 in San Francisco, with U.S. FDA approval of its Aurora extravascular implantable cardioverter-defibrillator (EV-ICD). The system delivers defibrillation and heart pacing without placing wires in the heart or vasculature. That puts it in direct competition with Boston Scientific Corp.’s Emblem S-ICD, currently the only player in the market.
RSS
